Singapore based BioFourmis, the world’s first personalised physiological data analytics firm today announced that the company has secured $1M in angel funding. The investment round was led by SpesNet and Eden Strategy.
BioFourmis is a healthcare data analytics company that specialises in offering predictive, precise and meaningful insights into one’s health. It has been actively working with the healthcare sector to offer predictive, precise and meaningful insights into one’s health.
With the increasing uptake of wearable technology and biosensors, there is an explosion of healthcare data being created daily. Our vision is to empower people by making personalised healthcare data understandable and actionable through cutting-edge technology.
said Kuldeep Singh, Founder & CEO, BioFourmis.
Its product Biovitals can intelligently read and interpret all types of data, no matter what its form. It interprets and fuses healthcare data from almost any source, creating highly optimised monitoring solutions and accurate health predictions.
So, Biovitals is basically a state-of-the art analytics engine that uses cognitive technology and advanced machine learning to provide actionable health insights. It intelligently interprets any form of data formulating personalized health models that are understandable and actionable displaying real-time patient information and physiological changes. Thus, it offers real-time suggestions for proactive and preventative healthcare actions especially in cardiovascular diseases.
Commenting further, Mark Niu, Co-Founder, BioFourmis said,
Whether you are a medical institution or nutritionist, care giver or corporate executive, our aim is to empower you to provide new healthcare services and solutions. Our aim is to break-away from the traditional population-based metrics and provide personalised health models.
BioFourmis is committed to pioneering world-class innovations to revolutionalise personalised healthcare. BioFourmis strives to transform the way health is understood and encourage preventive and proactive healthcare.
Mr Calvin Chu Yee Ming, Partner, Eden Strategy said,
We believe in BioFourmis’s promise of moving away from conventional healthcare systems and making it more personalised and real-time.
